Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Mitsubishi Tanabe Pharma partners MT210 with Cyrenaic Pharmaceuticals

Executive Summary

Mitsubishi Tanabe Pharma Corp. licensed Cyrenaic Pharmaceuticals Inc. exclusive rights outside of Asia (including China, Japan, India, and South Korea) to its Phase I 5-HT2A/Sigma-2 antagonist MT210 for schizophrenia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register